Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:36:05.770Z.
Consensus retrieved: 2026-10-06T09:50:50.076Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:36:05.770Z.
Quote observation: 2026-10-06T16:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 370e13d786cc28e63fbc6719e554b7ac483294971c86eef7c80c09e39811c756
Forward PE Ratio (N/A) = Dated Quote Price ($10.05) / Consensus Forward EPS ($-1.34)
FORWARD PE RATIO
N/A
Candel Therapeutics, Inc.
Market Cap
$736.73M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $736.73M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.09M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $739.74M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $717.39M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $758.23M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $710.13M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $708.40M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $707.01M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $767.66M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.34 | $-1.46 – $-1.08 | 4 | n/m |
| 2027-12-31 | $-1.07 | $-1.83 – $-0.16 | 4 | n/m |
| 2028-12-31 | $0.15 | $-2.81 – $3.89 | 6 | 65.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
